{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-012106","form_type":"8-K","ticker":"LMAT","cik":"0001158895","company_name":"LEMAITRE VASCULAR INC","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.078478+00:00","generated_at":"2026-06-16T02:43:02.680438+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LeMaitre Q1 sales up 22% organic to $47.1M; EPS flat at $0.27; issues guidance","bullets":["Sales $47.1M, +19% (+22% organic); net income $6.0M flat; diluted EPS $0.27 (-1%).","Valvulotomes (+29%), carotid patches (+17%), bovine grafts (+22%), allografts (+42%), carotid shunts (+18%) led record Q1 sales.","Q2 2023 guidance: sales $47.1M–$49.5M; EPS $0.30–$0.35. Full year: sales $187.1M–$193.1M; EPS $1.14–$1.27.","Quarterly dividend $0.14/share, payable June 1, 2023 to holders of record May 17, 2023.","Agreed to distribute Aziyo porcine cardiac patches in US for three years (option to acquire); Aziyo's 2022 US patch sales $6.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-012106","json":"https://secwatch.observer/filing/0001437749-23-012106.json","markdown":"https://secwatch.observer/filing/0001437749-23-012106.md","text":"https://secwatch.observer/filing/0001437749-23-012106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923012106/0001437749-23-012106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923012106/lmat20230502_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:43:02.680438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66b625e37767a558a3c30fe4b6a40e2cefcb70e2","claim":"LEMAITRE VASCULAR INC updated its the quarter ended March 31, 2023 guidance (initiated).","evidence_excerpt":"On May 2, 2023, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923012106/0001437749-23-012106-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"6be0f42da4976e132cd04d87da784ebfdf522d88","claim":"LEMAITRE VASCULAR INC reported Q1 2023 results: revenue $47.1mm, net income $6.0mm, EPS $0.27. Guidance initiated.","evidence_excerpt":"devices, implants and services, today reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q1 2023 Financial Results ● Sales $47.1mm, +19% (+22% organic) vs. Q1 2022 ● Op. income $7.9mm, -1% ● Op. margin 17% ● Net income $6.0mm, flat ● Earnings per diluted share $0.27, -1%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923012106/0001437749-23-012106-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2023"},{"label":"Revenue","value":"$47.1mm"},{"label":"Net income","value":"$6.0mm"},{"label":"EPS","value":"$0.27"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}